论文部分内容阅读
采用改良的MV1LU细胞生长抑制MTT法,检测了108例病毒性肝炎患者血清TGF-β活性和血清PCⅢ、HA、LN的含量,结果表明各型肝炎患者血清TGF-β活性较正常对照都明显增高(P<0.01)。随病情的发展,TGF-β1活性逐渐增高,PCⅢ、HA、LN含量也明显增加,慢迁肝、慢活肝、肝硬化各组间TGF-β1活性和PCⅢ、HA、LN含量均有显著性差异(P<0.01),并呈正相关。肝硬化合并肝癌患者血清TGF-β活性较正常对照增加10倍以上。作者认为TGF-β1活性可较好地反映肝纤维化进展状况,是调控肝纤维化的重要因子;肝硬化合并肝癌时,TGF-β1活性显著增高,提示其可作为肝癌诊断、预后判断的另一指标。
Using modified MV1LU cell growth inhibition MTT assay, the serum levels of TGF-β and serum PCⅢ, HA and LN in 108 patients with viral hepatitis were measured. The results showed that serum TGF-β activity in patients with various hepatitis was significantly higher than that in normal control (P <0.01). With the progression of the disease, the activity of TGF-β1 gradually increased and the content of PCⅢ, HA and LN also increased obviously. The contents of TGF-β1, PCⅢ, HA and LN in slow-moving liver, slow-living liver and cirrhosis were significantly higher Difference (P <0.01), and was positively correlated. Serum TGF-β activity in cirrhotic patients with hepatocellular carcinoma was more than 10 times higher than that in normal controls. The authors believe that TGF-β1 activity can better reflect the progress of liver fibrosis, is an important factor in the regulation of liver fibrosis; cirrhosis combined with liver cancer, TGF-β1 activity was significantly increased, suggesting that it can be used as a diagnosis of liver cancer, the prognosis of the other An indicator.